Quinapril Hydrochloride
Quinapril, via its active metabolite, quinaprilat, is an angiotensin converting enzyme inhibitor (ACEI) used in the treatment of high blood pressure and heart failure.
Oral administration every 12-24 hours.
It is excreted in breastmilk in clinically insignificant amounts (Anderson 2018, Begg 2001).
No problems have been observed in infants whose mothers were taking other ACEIs (Anderson 2018).
Due to its possible renal toxicity in preterm infants, it is preferable to avoid its use during the neonatal period in case of prematurity. (Serrano 2015).
The protective role of breastfeeding against maternal hypertension has been proven (Park 2018).
Very Low Risk
Compatible. Not risky for breastfeeding or infant.
Low Risk
Moderately safe. Mild risk possible. Follow up recommended. Read the Comment.
High Risk
Poorly safe. Evaluate carefully. Use a safer alternative. Read the Comment.
Very High Risk
Not recommended. Cessation of breastfeeding or alternative.
Writings
- Κιναπρίλη (Greek)
- Хинаприла Гидрохлорид (Cyrillic)
- キナプリル塩酸塩 (Japanese)
- C25 H30 N2 O5, HCl (Molecular formula)
- (3S)-2-{N-[(S)-1-Ethoxycarbonyl-3-phenylpropyl]-l-alanyl}-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid hydrochloride (Chemical name)
- C09A (ATC Code/s)
Drug trade names
References
- Park S, Choi NK. Breastfeeding and Maternal Hypertension. Am J Hypertens. 2018Abstract
- Anderson PO. Treating Hypertension During Breastfeeding. Breastfeed Med. 2018Abstract
- AEMPS. Quinapril. Ficha técnica. 2017 Full text (in our servers)
- Serrano Aguayo P, García de Quirós Muñoz JM, Bretón Lesmes I, Cózar León MV. Tratamiento de enfermedades endocrinológicas durante la lactancia. [Endocrinologic diseases management during breastfeeding.] Med Clin (Barc). 2015Abstract
- FDA. Quinapril. Drug Summary. 2013 Full text (in our servers)
- Begg EJ, Robson RA, Gardiner SJ, Hudson LJ, Reece PA, Olson SC, Posvar EL, Sedman AJ. Quinapril and its metabolite quinaprilat in human milk. Br J Clin Pharmacol. 2001Abstract